Secondary Hypercoagulable State Documentation Best Practices
Customize your policy alerts
Sign up for all wellsense_health_plan policy alerts
Know when wellsense_health_plan releases new policies or updates existing guidance.
Monitor payer policy activity
Guidance for clinicians on documenting secondary hypercoagulable states (eg, due to atrial fibrillation, COVID-19, or active cancer) to support accurate diagnosis capture and coding for Wellsense Health Plan members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Documentation sufficiency
Covered when ALL of the following documentation elements are present
Examples: atrial fibrillation, COVID-19, malignancy
Helps support coding to D68.69
Include treatment decisions (eg, anticoagulation guided by CHA2DS2-VASc) and follow-up plan
Inherited primary hypercoagulable disorders (for example, Factor V Leiden and protein C or S deficiencies) are not considered secondary hypercoagulable states and should not be documented as such. When the hypercoagulable state is due to an underlying condition, document the primary cause explicitly and use the diagnosis code D68.69 for secondary hypercoagulable state only when the linkage to a non‑inherited cause is clear.
Diagnosis Coding and Examples
| D68.69 | Other thrombophilia; Secondary hypercoagulable state |
| I48.19 | Other persistent atrial fibrillation |
| C50.911 | Primary Malignant Neoplasm of Right Female Breast |
| C79.51 | Secondary Malignant Neoplasm of Bone |
Provider Actions and Documentation Requirements
Diagnosis coding requirement: use D68.69 and specify primary cause
Document the secondary hypercoagulable state using ICD-10 code D68.69 and specify the primary cause (for example, atrial fibrillation or malignancy) to support medical necessity and accurate coding.
- Use diagnosis code D68.69 (Other thrombophilia; Secondary hypercoagulable state).
- Explicitly state the primary condition responsible (e.g., atrial fibrillation, malignancy) in the same assessment entry.
Additional provider actions for complete documentation
Ensure documentation includes clear statements that link the secondary hypercoagulable state to an underlying cause, document the status of the primary condition, and record an assessment and plan for both conditions.
- If applicable, record treatments related to both the primary condition and anticoagulation decisions (examples: continue Eliquis for atrial fibrillation; follow oncology treatment for malignancy).
- Include examples shown in the policy (atrial fibrillation, active cancer) when documenting similar cases.
Required documentation elements
Include the primary condition responsible for the hypercoagulable state, use explicit linking language (for example, 'due to', 'secondary to', 'caused by', or 'associated with'), and document assessment and plan for both the primary and secondary conditions.
- Document the primary diagnosis and its status (e.g., other persistent atrial fibrillation I48.19; primary and secondary malignancy codes).
- Record treatment decisions and follow-up for both the primary condition and the secondary hypercoagulable state (e.g., anticoagulation management).
Risk: missing linkage may cause denial or miscoding
Failure to identify the primary condition causing the hypercoagulable state or to explicitly link the secondary condition back to the primary diagnosis may result in improper diagnosis capture and administrative denials or miscoding.
- Omitting linking language (eg, 'due to', 'secondary to') risks denial or coding errors.
- Not documenting assessment and plan for both conditions may undermine medical necessity justification.
Background
A secondary hypercoagulable state describes an increased risk of thromboembolism that is caused by an underlying disease or condition. Common examples include hypercoagulability associated with atrial fibrillation and COVID‑19. By definition, this term excludes inherited or primary thrombophilias such as Factor V Leiden or protein C or S deficiencies. Use clinical documentation to name the primary condition and explicitly link it to the secondary hypercoagulable state to support accurate coding and management.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.